Smith+Nephew’s performance in Established Markets was strong, with 4.1% underlying growth, while Emerging Markets, excluding China, showed a 14.7% growth. The company continues to face challenges in ...

In other recent news, Smith+Nephew reported strong financial results for 2024, with revenue increasing to $5.81 billion from $5.55 billion in 2023, reflecting a 5.3% underlying revenue growth.

Despite the headwinds, Smith+Nephew has reaffirmed its full-year 2025 guidance, projecting an underlying revenue growth of about 5.0% and reported growth of 5.4%.

Smith & Nephew delivered strong fourth-quarter performance with underlying revenue growth of 8% and operating margin improvement of 360 basis points. Why it matters: Management's consistent focus ...

Smith & Nephew (NYSE: SNN) announced its Q3 results on the 31st of October. Guidance for FY24 was reduced citing the impact of lower demand from China. Share prices closed down 13% on the ...

Hip arthroscopy helps to stage the disease 30 and detect osteochondral degeneration, which cannot be identified by plain radiographs and MRI, particularly in post-collapse femoral heads. 31 ...

In 2023, ambulatory surgery centers, especially physician-owned ones, surged in arthroscopic procedures, pushing suppliers for competitive pricing, curbing inflation, and limiting market growth ...